StockNews.com Begins Coverage on Invitae (NYSE:NVTA)

StockNews.com began coverage on shares of Invitae (NYSE:NVTA) in a research report report published on Tuesday morning. The firm issued a hold rating on the medical research company’s stock.

Invitae Trading Down 94.4 %

Invitae stock opened at $0.00 on Tuesday. The firm has a market capitalization of $133,505.00, a P/E ratio of 0.00 and a beta of 1.59. Invitae has a 1 year low of $0.02 and a 1 year high of $0.02. The business has a 50-day moving average of $0.01 and a 200-day moving average of $0.34.

Hedge Funds Weigh In On Invitae

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in shares of Invitae during the 3rd quarter valued at about $29,000. Longitude Cayman Ltd. lifted its stake in Invitae by 29.3% in the 3rd quarter. Longitude Cayman Ltd. now owns 776,000 shares of the medical research company’s stock valued at $470,000 after acquiring an additional 176,000 shares in the last quarter. ARK Investment Management LLC lifted its stake in Invitae by 2.1% in the 3rd quarter. ARK Investment Management LLC now owns 32,942,606 shares of the medical research company’s stock valued at $19,937,000 after acquiring an additional 679,672 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Invitae by 4.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock valued at $1,000,000 after acquiring an additional 64,228 shares in the last quarter. Finally, Harbor Capital Advisors Inc. lifted its stake in Invitae by 24.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 224,642 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 43,642 shares in the last quarter. Institutional investors own 61.28% of the company’s stock.

Invitae Company Profile

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.